Human growth hormone ($3 billion market, entering Phase II) that could potentially be injected twice per month instead of daily injections. Interferon beta for multiple sclerosis ($4.5 billion market) that may have dramatically lower side effects. Our CTP-enhanced therapeutic proteins pipeline has the potential to dominate a $25 billion market.
CTP is a small peptide naturally found in the body as a portion of the hormone hCG, and in fact provides hCG with its superior longevity. We attach CTP to other proteins and significantly increase their lonevity as well.
Merck and PROLOR have the exclusive license from Washington University to utilize the CTP technology. On January 28, 2010 the European Commission (EC) gave Merck & Co. marketing approval with unified labeling valid in all European Union Member States for FSH-CTP, now branded as ELONVA®.
"I think Prolor is a great little company, and its small size is one of its main virtues. It is run and managed carefully by hard-working people who get things done efficiently. They currently have half-a-dozen drugs under development, each of which has the potential for over $1 billion in sales."
Data Show PROLOR’s Biobetter Form of hGH has Potential to Reduce Required Dosing Frequency from One Injection Per Day to Two Injections Per Month. Phase I Safety and Tolerability Endpoints Met.
Merck and PROLOR are Both Licensees of the CTP Technology Used to Prolong the Duration of Merck’s Novel Fertility Drug ELONVA®. Supports the Clinical Efficacy and Safety of CTP Technology.
Primate Study Shows Durability of PROLOR’s IFN-Beta-CTP Is Prolonged 13 Times and Drug Exposure is Prolonged 55 Times Compared to Commercially Available IFN-Beta. By Decreasing Frequency of Required Injections, IFN-Beta-CTP Could Provide Important Benefits to Multiple Sclerosis Patients
.gif)
Chairman & CEO of NYSE, Duncan L. Niederauer, hosted a breakfast and bell-ringing ceremony to celebrate PROLOR's recent listing with NYSE